Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Penthienate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 known ✓ | P11229 | 11/20 | 0.67 |
| ▸ | CHRM2 known ✓ | P08172 | 10/20 | 0.67 |
| ▸ | CHRM3 known ✓ | P20309 | 10/20 | 0.66 |
| ▸ | CHRM4 known ✓ | P08173 | 3/20 | 0.66 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.67 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | SCN1A | P35498 | 2/20 | 0.42 |
| ▸ | SCN2A | Q99250 | 2/20 | 0.42 |
| ▸ | SCN3A | Q9NY46 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Penthienate SCHEMBL31393386 | 0.99 | CHRM1 (0.68) | CHRM1CHRM2SLC6A3KCNH2CHRM3 | |
| Penthienate SCHEMBL28086303 | 0.94 | CHRM1 (0.62) | CHRM1CHRM2SLC6A3KCNH2CHRM3 | |
| SCHEMBL15095409 | 0.84 | CHRM2 (0.62) | CHRM1CHRM2SLC6A3KCNH2CHRM3 | |
| SCHEMBL2795158 | 0.82 | CHRM2 (0.73) | CHRM1CHRM2SLC6A3KCNH2CHRM3 | |
| Oxyphenonium SCHEMBL248890 | 0.81 | CHRM2 (0.98) | CHRM1CHRM2SLC6A3KCNH2CHRM3 | |
| Penthienate SCHEMBL5886141 | 0.81 | CHRM1 (0.49) | CHRM1CHRM2SLC6A3KCNH2CHRM3 | |
| Oxyphenonium SCHEMBL250615 | 0.80 | CHRM2 (1.00) | CHRM1CHRM2SLC6A3KCNH2CHRM3 | |
| Oxyphenonium SCHEMBL250614 | 0.80 | CHRM2 (1.00) | CHRM1CHRM2SLC6A3KCNH2CHRM3 | |
| Oxyphenonium SCHEMBL2030870 | 0.79 | CHRM2 (0.98) | CHRM1CHRM2SLC6A3KCNH2CHRM3 | |
| SCHEMBL1234853 | 0.78 | CHRM3 (0.63) | CHRM1CHRM2CHRM3CHRM4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 456 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250032503-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | HOTH THERAPEUTICS, INC. | 2025-01-30 | — | — | US | claimed |
| EP-4297868-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | Hoth Therapeutics, Inc. (US) | 2024-01-03 | — | — | EP | claimed |
| WO-2022182658-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | HOTH THERAPEUTICS, INC. (US) | 2022-09-01 | — | — | WO | claimed |
| WO-2017147104-A1 | MUSCARINIC M2-ANTAGONIST COMBINATIONS | CHASE PHARMACEUTICALS CORPORATION (US) | 2017-08-31 | — | — | WO | claimed |
| US-20140171645-A1 | ELECTROPHILIC ALKYLATING REAGENTS, THEIR PREPARATION AND USE | HOVIONE INTER LTD. (CH) | 2014-06-19 | — | — | US | claimed |
| EP-2691367-A1 | ELECTROPHILIC ALKYLATING REAGENTS, THEIR PREPARATION AND USE | Hovione Inter Ltd. (CH) | 2014-02-05 | — | — | EP | claimed |
| CN-103502211-A | Electrophilic alkylating reagents, preparation and use thereof | HOVIONE FARMACIENCIA S A | 2014-01-08 | — | — | CN | claimed |
| WO-2012131286-A1 | ELECTROPHILIC ALKYLATING REAGENTS, THEIR PREPARATION AND USE | HOVIONE INTER. LTD (CH) | 2012-10-04 | — | — | WO | claimed |
| EP-1273301-B1 | Pharmaceutical preparations based on active ingredients susceptible to illicit administration | ALTERGON SA (CH) | 2006-09-06 | — | — | EP | claimed |
| CN-1520818-A | Cholinesterase inhibitor pharmaceutical composition for senile dementia | ɽ����Ҷ��Ȼҩ���о���������˾ | 2004-08-18 | — | — | CN | claimed |
| EP-1273301-A2 | Pharmaceutical preparations based on active ingredients susceptible to illicit administration | ALTERGON S.A. (CH) | 2003-01-08 | — | — | EP | claimed |
| CN-1294519-A | Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient | INPHARMA SA (CH) | 2001-05-09 | — | — | CN | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| US-5008111-A | Pretreating skin with anticholinergic quaternary ammonium salt to suppress perspiration | SCHERING CORPORATION (US) | 1991-04-16 | — | — | US | claimed |
| US-4824676-A | ANTICHOLINERGIC AGENT TO SUPPRESS PERSPIRATION | SCHERING CORPORATION (US) | 1989-04-25 | — | — | US | claimed |
| EP-0140434-A2 | Pharmaceutical composition with systemic anticholineesterasic, agonistic-cholinergic and antimuscarinic activity | PRODOTTI FORMENTI S.r.l. (IT) | 1985-05-08 | — | — | EP | claimed |
| US-20260125364-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | PFIZER (US) | 2026-05-07 | — | — | US | disclosed |
| WO-1986002272-A1 | PHYSIOLOGICAL MEANS OF ENHANCING TRANSDERMAL DELIVERY OF DRUGS | KEY PHARMACEUTICALS, INC. (US) | 1986-04-24 | — | — | WO | disclosed |
| EP-0140434-A2 | Pharmaceutical composition with systemic anticholineesterasic, agonistic-cholinergic and antimuscarinic activity | PRODOTTI FORMENTI S.r.l. (IT) | 1985-05-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260125364-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | HTR6, HTR3C, OPRD1 | CHRM1 87/4885CHRM2 115/4885CHRM3 143/4885 |
| US-20250032503-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | TACR1, ACHE, TACR2 | CHRM1 286/4885CHRM2 158/4885CHRM3 82/4885 |
| US-20140171645-A1 | ELECTROPHILIC ALKYLATING REAGENTS, THEIR PREPARATION AND USE | MGMT, MCL1, TOP2B | CHRM1 3157/4885CHRM2 2607/4885CHRM3 3125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.